Postoperative anti-PD-1 antibody treatment to reduce recurrence in a cancer ablation surgical wound.

[1]  S. Pai,et al.  The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. , 2016, Oral oncology.

[2]  T. B. Bakker Schut,et al.  Resection margins in oral cancer surgery: Room for improvement , 2016, Head & neck.

[3]  L. Howie,et al.  Neoadjuvant use of ipilimumab in locally advanced melanoma , 2015, Journal of surgical oncology.

[4]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[5]  M. Azuma,et al.  Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. , 2015, Oral oncology.

[6]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[7]  J. Lunceford,et al.  LBA31A PHASE IB STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH HUMAN PAPIILLOMA VIRUS (HPV)-POSITIVE AND NEGATIVE HEAD AND NECK CANCER (HNC) , 2014 .

[8]  A. Vecchione,et al.  Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling , 2014, Oncotarget.

[9]  J. Kirkwood,et al.  Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab , 2014, PloS one.

[10]  D. Davar,et al.  Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. , 2013, Clinics in dermatology.

[11]  S. Ben-Eliyahu,et al.  Surgery and stress promote cancer metastasis: New outlooks on perioperative mediating mechanisms and immune involvement , 2013, Brain, Behavior, and Immunity.

[12]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[13]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[14]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[15]  Drew M Pardoll,et al.  Cancer immunotherapy comes of age. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Kaplan,et al.  Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer , 2011, Head & neck.

[17]  W. Zou,et al.  Dual biological effects of the cytokines interleukin-10 and interferon-γ , 2011, Cancer Immunology, Immunotherapy.

[18]  D. Parés,et al.  Randomized clinical trial comparing inflammatory and angiogenic response after open versus laparoscopic curative resection for colonic cancer , 2011, The British journal of surgery.

[19]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Durieux,et al.  The Role of the Perioperative Period in Recurrence After Cancer Surgery , 2010, Anesthesia and analgesia.

[21]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[22]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[23]  M. Ohira,et al.  N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma , 2008, Oncogene.

[24]  T. Cotter,et al.  Mechanisms Driving Local Breast Cancer Recurrence in a Model of Breast-Conserving Surgery , 2008, Annals of Surgical Oncology.

[25]  K. Tanabe,et al.  Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.

[26]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[27]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[28]  Jeung-Hoon Lee,et al.  IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. , 2005, Journal of dermatological science.

[29]  R. Demicheli,et al.  Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  T. Cotter,et al.  Phosphoinositide 3-Kinase Accelerates Postoperative Tumor Growth by Inhibiting Apoptosis and Enhancing Resistance to Chemotherapy-induced Apoptosis , 2005, Journal of Biological Chemistry.

[31]  Michael Höckel,et al.  The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. , 2005, Cancer research.

[32]  A. Chambers,et al.  Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. , 2005, Cancer research.

[33]  Naphtali Abudarham,et al.  Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a β-adrenergic antagonist and a prostaglandin synthesis inhibitor , 2005, Brain, Behavior, and Immunity.

[34]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[35]  M. Ohira,et al.  Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas. , 2004, International journal of oncology.

[36]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[37]  M. Kattan,et al.  Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. , 2003, Cancer research.

[38]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[40]  Y. Takagi,et al.  Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. , 2000, Annals of surgery.

[41]  W. Jarnagin,et al.  Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. , 2000, Annals of surgery.

[42]  A. De Benedetti,et al.  Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Shakhar,et al.  Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity , 1999, International journal of cancer.

[44]  R H Hruban,et al.  Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[45]  S. Ben-Eliyahu,et al.  Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. , 2006, Breast disease.

[46]  Ray H. Baughman,et al.  Supporting Online Material , 2003 .

[47]  M. Neeman,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0223 Stimulation of tumour growth by wound-derived growth , 2022 .